Crossmark

VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist

Crossref DOI link: https://doi.org/10.1016/j.reumae.2015.11.020

Published Print: 2016-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Torrente-Segarra, Vicenç

Acosta Pereira, Asunción

Morla, Rosa

Ruiz, José Miguel

Clavaguera, Teresa

Figuls, Ramon

Corominas, Hector

Geli, Carme

Roselló, Rosa

de Agustín, Juan José

Alegre, Cayetano

Pérez, Carolina

García, Angel

Rodríguez de la Serna, Arturo
License Information

Text and Data Mining valid from 2016-11-01
More Information

This article is maintained by: Elsevier

Article Title: VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2015.11.020

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2015.11.019

Content Type: simple-article

Copyright: © 2015 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below